CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026

CalciMedica, Inc.

2025-Q2 EPS reported -$0.76 vs consensus -$0.36 ▼ miss (-112.9%)

Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.
Cash and investments $18.0M; expected to fund operations into mid-2026.
R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.
Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.
Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.